In this issue:
Semaglutide treatment in patients with diabetic kidney disease
A phase 2 trial of felzartamab for antibody-mediated rejection of kidney transplants
Projecting the economic burden of CKD at the patient level
Hypertension and kidney function after living kidney donation
Electronic health record-based management intervention for CKD
Impact of SGLT2i treatment on the risk of dialysis and cardiovascular disease in stage 5 CKD
Use of a kidney failure risk equation for triaging CKD patients
Plasma KIM-1 for prediction of renal cell carcinoma
Real-world effectiveness of preventive pharmacological therapy in patients with urolithiasis
Association of inflammatory bowel disease with incident IgA nephropathy
Please login below to download this issue (PDF)